Страна: Канада
Язык: английский
Источник: Health Canada
RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE)
NT PHARMA CANADA LTD
M05BA07
RISEDRONIC ACID
5MG
TABLET
RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 5MG
ORAL
30
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0135301002; AHFS:
CANCELLED PRE MARKET
2017-03-16
PRODUCT MONOGRAPH PR NTP-RISEDRONATE Risedronate sodium (as the monohydrate) 5 mg, 30 mg and 35 mg Tablets Bone Metabolism Regulator NT Pharma Canada Ltd. 5691 Main Street Stouffville, Ontario Canada, L4A 1H5 Submission Control No: 156479 Date of Revision: July 26, 2012 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 6 DRUG INTERACTIONS ......................................................................................................... 11 DOSAGE AND ADMINISTRATION ..................................................................................... 13 OVERDOSAGE ....................................................................................................................... 14 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 15 STORAGE AND STABILITY ................................................................................................. 19 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 19 PART II: SCIENTIFIC INFORMATION ............................................................................... 21 PHARMACEUTICAL INFORMATION ................................................................................. 21 CLINICAL TRIALS ................................................................................................................. 22 Прочитать полный документ